机译:Carfilzomib沙利度胺和地塞米松在对复发/难治性多发性骨髓瘤的治疗中是安全可有效的:来自开放标签期II的初步结果ALLGMM018 / AMN003研究
St Vincents Hosp Dept Haematol Fitzroy Vic Australia;
Peter MacCallum Canc Ctr Clin Haematol Melbourne Vic Australia;
St Vincents Hosp Dept Haematol Fitzroy Vic Australia;
Concord Hosp Concord Canc Ctr Haematol Dept Concord NSW Australia;
Royal Adelaide Hosp Dept Haematol SA Pathol Adelaide SA Australia;
Royal Hobart Hosp Hobart Tas Australia;
Border Med Oncol Albury NSW Australia;
Sir Charles Gairdner Hosp Dept Haematol Nedlands WA Australia;
Univ Hosp Geelong Geelong Vic Australia;
Middlemore Hosp Auckland New Zealand;
Royal Darwin Hosp Casuarina Australia;
Australasian Leukaemia &
Lymphoma Grp Melbourne Vic Australia;
WriteSource Med Pty Ltd Lane Cove Australia;
Australasian Leukaemia &
Lymphoma Grp Melbourne Vic Australia;
Princess Alexandra Hosp Brisbane Qld Australia;
Cedars Sinai Outpatient Canc Ctr Samuel Oschin Comprehens Canc Inst Los Angeles CA USA;
Natl Univ Canc Inst Singapore Singapore Singapore;
机译:Carfilzomib沙利度胺和地塞米松在对复发/难治性多发性骨髓瘤的治疗中是安全可有效的:来自开放标签期II的初步结果ALLGMM018 / AMN003研究
机译:Isatuximab Plus Carfilzomib / DexameLasone与复发/难治性多发性骨髓瘤患者的Carfilzomib /地塞米松:Ikema第III期研究设计
机译:Carfilzomib,Pomalidomide和地塞米松在复发和/或难治性多发性骨髓瘤(MM)患者中的多中心,开放标签I / II期研究
机译:单药羟基脲的第II期开放标签研究,用于治疗犬晚皮腰肿瘤瘤
机译:Ixazomib的第1/2期作为替代品髓鞘或胭脂瘤患者的替代品的替代物,最近对含有Bortezomib或Carfilzomib的最后组合方案复发或难治
机译:伏立诺他硼替佐米阿霉素和地塞米松在I / II期研究中对复发或难治性多发性骨髓瘤的安全性和有效性(VERUMM研究:伏立诺他用于老年复发和不适的多发性骨髓瘤)
机译:在用Lenalidomide和Bortezomib治疗后,研究II期试验,以研究弯曲蛋白,地塞米松,摩天蛋白酶,地塞米松和沙利度族的疗效和安全性复发或难治多骨髓瘤患者